24/7 Market News Snapshot 23 June, 2025 – Carisma Therapeutics, Inc. Common Stock (NASDAQ:CARM)

June 23, 2025

DENVER, Colo., 23 June, 2025 (www.247marketnews.com) – (NASDAQ:CARM) are discussed in this article.
Carisma Therapeutics Inc. is currently experiencing a notable surge in market activity, with its shares trading at $0.513 during the pre-market session, representing a 16.3% increase from the previous close of $0.441. This uptick is indicative of strong investor interest, as evidenced by a significant trading volume of 8.52 million shares. Analysts suggest that if Carisma maintains levels above critical support, it may signal the continuation of this bullish trend. Observing resistance levels and volume trends will be crucial for predicting future price movements, providing investors with insight into the stock’s trajectory.

In a strategic move to bolster its position in regenerative medicine, Carisma has announced a definitive merger with OrthoCellix, Inc., a subsidiary of Ocugen, Inc. This all-stock transaction aims to unite Carisma’s innovative macrophage engineering platform with OrthoCellix’s advanced NeoCart® technology, designed to address critical needs in treating orthopedic diseases, especially knee cartilage defects. NeoCart® is a Phase 3-ready autologous cartilage implant technology that utilizes patient cells to repair articular cartilage damage, offering the potential for faster recovery and enhanced patient outcomes.

Dr. Shankar Musunuri, CEO of Ocugen, emphasized the merger as an exceptional opportunity to exploit NeoCart®’s potential while creating lasting value for stakeholders. Steven Kelly, President and CEO of Carisma, echoed this sentiment, highlighting that the merger positions the combined entity for substantial growth within the regenerative medicine sector. Following the merger’s anticipated completion in late 2025, the newly formed company will operate under the name OrthoCellix, Inc., trading as ‘OCLX’ on Nasdaq. This collaboration underscores a commitment to pioneering advancements in regenerative therapies, aiming to improve care for patients facing orthopedic challenges.

Related news for (CARM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.